Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (129)

1

Ribociclib plus Endocrine Therapy in Early Breast Cancer

enthalten in: The New England journal of medicine | 2024

von Slamon, D. | Lipatov, O. | Nowecki, Z. | +28

2

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination : A Phase 3 Randomized Clinical Trial

enthalten in: JAMA oncology | 2024

von Ma, C. | Suman, V. | Sanati, S. | +27

3

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy

enthalten in: Breast cancer research and treatment | 2023

von Iwata, H. | Yamamoto, Y. | Sakai, T. | +12

4

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer : Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

enthalten in: Targeted oncology | 2022

von De Laurentiis, M. | Caputo, R. | Mazza, M. | +18

5

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Bidard, F. | Hardy-Bessard, A. | Dalenc, F. | +115

CommentIn: Nat Rev Clin Oncol. 2023 Feb;20(2):67-68. - PMID 36424404

6

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer : Results From the Randomized Phase III EMERALD Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Bidard, F. | Kaklamani, V. | Neven, P. | +26

CommentIn: J Clin Oncol. 2022 Oct 1;40(28):3227-3229. - PMID 35737918

7

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer

enthalten in: Future oncology (London, England) | 2022

von Pérez-Fidalgo, J. | Criscitiello, C. | Carrasco, E. | +5

8

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : subgroup analysis of the phase IIIb CompLEEment-1 trial

enthalten in: Breast cancer research and treatment | 2022

von Campone, M. | De Laurentiis, M. | Zamagni, C. | +8

9

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer : The MA.32 Randomized Clinical Trial

enthalten in: JAMA | 2022

von Goodwin, P. | Chen, B. | Gelmon, K. | +21

CommentIn: Endocr Pract. 2022 Aug;28(8):832-834. - PMID 35724834

10

Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy : subgroup safety analysis from the phase 3b CompLEEment-1 trial

enthalten in: Radiology and oncology | 2022

von Borstnar, S. | Palacova, M. | Łacko, A. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]